Document Detail

Urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants.
MedLine Citation:
PMID:  18410782     Owner:  NLM     Status:  MEDLINE    
Hematopoietic and non-hematopoietic effects of recombinant erythropoietin (Epo) given to preterm infants are controversially discussed. Because renal loss of Epo was significantly higher after intravenous versus subcutaneous Epoetin-beta administration, we suggest a reconsideration of whether subcutaneous recombinant Epo is more efficient and safer because of lower peaks of circulating Epo.
Juliane Langer; Michael Obladen; Christof Dame
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  152     ISSN:  1097-6833     ISO Abbreviation:  J. Pediatr.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-15     Completed Date:  2008-05-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  728-30     Citation Subset:  AIM; IM    
Klinik für Neonatologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Neonatal / drug therapy*,  urine*
Erythropoietin, Recombinant / administration & dosage*,  pharmacokinetics*
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / drug therapy*,  urine*
Infant, Very Low Birth Weight
Injections, Intravenous
Injections, Subcutaneous
Longitudinal Studies
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/epoetin beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families.
Next Document:  Neonatal vitamin B12 deficiency secondary to maternal subclinical pernicious anemia: identification ...